Business Wire

CA-VERIMATRIX

29.6.2020 17:47:05 CEST | Business Wire | Press release

Share
Altibox Norway Takes Verimatrix End-to-End Security into the Cloud

Verimatrix , (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Altibox Norway , one of the largest regional telecommunication operators throughout Norway and Denmark, is one of the latest European customers to move its security framework into the Verimatrix Secure Cloud.

The move enables Altibox to take advantage of a flexible Software-as-a-Service (SaaS) model to host Verimatrix Multi-DRM , as well as hosting its existing Verimatrix Video Content Authority System (VCAS™) for IPTV. With the Verimatrix Secure Cloud, Altibox can more easily optimize its end-to-end content security with greater flexibility, ease of scale and lower costs.

Scheduled to be rolled out this year, the transition greatly simplifies Altibox’s management of its popular service offering relied upon by more than half a million subscribers. The cloud-managed Verimatrix Multi-DRM and VCAS for IPTV solutions also keep Altibox in continuous compliance with studio-required changes in security regimes, including MovieLabs specifications for 4K/UHD content.

“A seamless cloud security infrastructure is crucial for continually enhancing our ability to scale as demand grows,” said Jarle Johnsen, Head of TV technology at Altibox. “Moving to a content security management platform in the cloud with a trusted partner like Verimatrix empowers us to better meet growing needs as well as consistently exceed our customers’ expectations – all while attaining well-defined business objectives.”

“We’re happy that Altibox has reached to the cloud and adopted our SaaS model for Multi-DRM and VCAS,” said Asaf Ashkenazi, COO of Verimatrix.” With more of its security framework now managed within the Verimatrix Secure Cloud, Altibox can powerfully protect their revenue from fraud and gain further peace of mind through significantly enhanced reliability.”

To learn more about Verimatrix Multi-DRM and VCAS solutions and the benefits of the Verimatrix Secure Cloud, click here .

About Altibox
Altibox is a unified brand name for Broadband, IPTV and VoIP services distributed in Norway and Denmark with over 35 local Norwegian and 6 Danish FTTH networks. Altibox was set up by Southwestern Norwegian multi-utility firm Lyse Energi in 2002 under the name Lyse Tele. Lyse Tele is made up of the wholly-owned digital TV & broadband provider Altibox AS, and Lyse’s ownership stake in several fibre providers in Norway and Denmark. The national backbone network of Altibox covers all of Norway, from Agder in the south to Finmark in the north. Lyse Tele has 330,000 fibre customers, distributed across Norway. In addition, Altibox provides services to other network operators/owners. In total, more than 600,000 consumers and businesses get their internet and TV entertainment from Altibox. For more information visit www.altibox.no .

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye